IVX-A12 for Healthy Older Adults
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a new vaccine called IVX-A12, which aims to protect older adults aged 60 to 75 from two respiratory viruses, RSV and hMPV. The vaccine works by using harmless particles that mimic the viruses, helping the immune system learn to fight them.
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications. However, if you are on medications that affect the immune system, like high-dose corticosteroids or immunosuppressive drugs, you may not be eligible to participate.
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single intramuscular injection of the IVX-A12 vaccine or placebo on Day 0
Follow-up
Participants are monitored for safety and immunogenicity, with assessments of antibody titers and serum neutralization antibodies
What Are the Treatments Tested in This Trial?
Interventions
- IVX-A12
Find a Clinic Near You
Who Is Running the Clinical Trial?
Icosavax, Inc.
Lead Sponsor